Skip to main content
Program
Login Required
Poster Gallery
Browse by Category
Browse by Poster Number
Browse by Title
Browse by Author
Poster Wall
Sponsors
Exhibits
Exhibit Hall
Exhibitor List
Restricted Access
Delegates
Speakers
Attendees
CE Information/Evaluation
CE Information
Faculty Disclosures
Evaluation/Claim CE
iwCLL Committees & Membership
FAQ
Toggle navigation
Login
Search
Home
Program
Login Required
Poster Gallery
Browse by Category
Browse by Poster Number
Browse by Title
Browse by Author
Poster Wall
Sponsors
Exhibits
Exhibit Hall
Exhibitor List
Restricted Access
Delegates
Speakers
Attendees
CE Information/Evaluation
CE Information
Faculty Disclosures
Evaluation/Claim CE
iwCLL Committees & Membership
FAQ
iwCLL X / Twitter
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Tweet
Jacopo Olivieri, MD
Clinica Ematologia di Udine, Italy
NA
Poster(s):
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
1201 - Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
1203 - Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.
2018 - Over-Time Monitoring of CXCR4dim/CD5bright Proliferative Fraction Anticipates Relapse In Ibrutinib-Treated CLL : a reservoir for BTK mutations?
Back to Top
